Jiangsu GDK Biotechnology Co Ltd (688670) - Total Assets
Based on the latest financial reports, Jiangsu GDK Biotechnology Co Ltd (688670) holds total assets worth CN¥1.48 Billion CNY (≈ $216.00 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Jiangsu GDK Biotechnology Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Jiangsu GDK Biotechnology Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Jiangsu GDK Biotechnology Co Ltd for net asset value and shareholders' equity analysis.
Jiangsu GDK Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu GDK Biotechnology Co Ltd's total assets of CN¥1.48 Billion consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.4% |
| Accounts Receivable | CN¥112.96 Million | 7.4% |
| Inventory | CN¥34.93 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥80.65 Million | 5.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Jiangsu GDK Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688670 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu GDK Biotechnology Co Ltd's current assets represent 38.0% of total assets in 2024, an increase from 4.5% in 2017.
- Cash Position: Cash and equivalents constituted 5.4% of total assets in 2024, up from 0.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 9.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 7.4% of total assets.
Jiangsu GDK Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Jiangsu GDK Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Jiangsu GDK Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.43 | 3.37 | 0.44 |
| Quick Ratio | 1.98 | 3.10 | 0.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥295.19 Million | CN¥436.78 Million | CN¥-194.33 Million |
Jiangsu GDK Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu GDK Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -6.0% |
| Total Assets | CN¥1.53 Billion |
| Market Capitalization | $266.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu GDK Biotechnology Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu GDK Biotechnology Co Ltd's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu GDK Biotechnology Co Ltd (2017–2024)
The table below shows the annual total assets of Jiangsu GDK Biotechnology Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.53 Billion ≈ $224.31 Million |
-6.05% |
| 2023-12-31 | CN¥1.63 Billion ≈ $238.75 Million |
-10.68% |
| 2022-12-31 | CN¥1.83 Billion ≈ $267.31 Million |
+4.12% |
| 2021-12-31 | CN¥1.75 Billion ≈ $256.74 Million |
+125.52% |
| 2020-12-31 | CN¥777.98 Million ≈ $113.84 Million |
+95.82% |
| 2019-12-31 | CN¥397.30 Million ≈ $58.14 Million |
+27.59% |
| 2018-12-31 | CN¥311.39 Million ≈ $45.57 Million |
+4.47% |
| 2017-12-31 | CN¥298.06 Million ≈ $43.62 Million |
-- |
About Jiangsu GDK Biotechnology Co Ltd
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia. The company was founded in 2008 and is based in Taizhou,… Read more